Diagnostic delay in #SpA 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay was 6.6 years 🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA 🔹️Associated with type of initial symptoms (shorter in peripheral) POS0909 #EULAR2025 @rheumnow https://t.co/3BMYFxbKiq

• https://x.com/Nellziade/status/1933284700258283807/photo/1

Prédiction of PsA from PsO. Stockholm cohort, n=672): •PsA incidence 21.1/1000 PY. •AUC 0.80 for both referral and prognostic models. •Predictors: HLA-B27, uveitis, enthesial pain, TJC, hsCRP, BMI, SAA, GlycA. •Early identification feasible. Abstract OP0178 @RheumNow https://t.co/dxdChN6VZy

• https://x.com/synovialjoints/status/1933178050859962663/photo/1

Do the sites of clinical onset of PsA (i.e., swelling) correspond to those that, at the time of enrollment in the study, showed evidence of joint tenderness and/or ultrasound-detected alterations compatible with inflammation? Of 28 incident PsA cases, 68% had prior subclinical https://t.co/rAZJU6Va5x

• https://x.com/synovialjoints/status/1933179112287264951/photo/1

Study on the HLAs associated with the occurrence and course of acute/tender dactylitis in PsA patients. Acute dactylitis genetics: •HLA-B27 (OR 1.71), HLA-C12 (OR 1.43), B38/C12 & B27/C02 haplotypes. •Resolution faster on b/tsDMARDs (HR 1.67); unaffected by HLA. Abstract

GRAPPA defines : - D2T-PsA (failed ≥3 therapies incl. ≥2 b/tsDMARDs) - CM(complex to manage)-PsA (adds pain, comorbidity, complexity). A needed framework to improve trial design & real-world care. Do these definitions fit your clinic? #OP0175 @RheumNow #EULAR2025 https://t.co/ot1bVLIYLA

• https://x.com/JihaRheum/status/1933084357042008555/photo/1

29% of new-onset psoriasis pts in Stockholm cohort developed PsA over 9,255 person-years. Two prediction models (AUC 0.804) identify: ➡ who to refer ➡ who will progress Key predictors: HLA-B27, CRP, enthesitis, arthralgia. @RheumNow #EULAR2025 #OP0178:

OP0176: Among D2T PsA pts, 43% lacked inflammation on imaging—despite symptoms. Clinical + US split them into PIPsA vs NIPsA, helping distinguish who needs escalation vs who doesn’t. A step toward smarter care in D2T PsA. @RheumNow #EULAR2025 https://t.co/E9igwvDPPN

• https://x.com/JihaRheum/status/1933087629345718777/photo/1

FAPI-PET/CT - detecting synovial and enthesial fibroblast activation- predicts the development of #psoriatic_arthritis in patients with psoriasis and arthralgia ✨️ A promising tool for early diagnosis of PsA Giulia Corte et al. OP#0174 #EULAR2025 @RheumNow https://t.co/QVmoECIhBI

• https://x.com/Nellziade/status/1933089071397564765/photo/1

✨️ New Definition Alert The GRAPPA definition of C2M (Complex to Manage) & D2T (Difficult to Treat) #Psoriatic_arthritis A hope for having a homogeneous and widely accepted definition for future clinical research Presented at #EULAR2025 Proft et al. OP#0175 @RheumNow https://t.co/et9cuMROkb

• https://x.com/Nellziade/status/1933091853680648484/photo/1

OP0179: In a psoriasis cohort, 68% of PsA onset sites showed prior subclinical inflammation (26% tender, 32% US+, 42% both). Should we redefine when PsA truly begins? @RheumNow #EULAR2025

In D2T-PsA (10%), 57% had persistent inflammation (PIPsA), 43% non-inflammatory (NIPsA). Ultrasound distinguished phenotypes: median US activity score 3.22 vs 0.88.,swollen joints 2.5 vs 0, tender points higher in NIPsA. Abstract OP0176 @RheumNow #EULAR2025 https://t.co/k7m8gAzbAZ

• https://x.com/synovialjoints/status/1933123344791961949/photo/1

Nordic registries (n=13,872): D2T-PsA varied 37% (≥2 b/tsDMARDs failed) to 0.6% (strictest). Female predominance increased with therapy failures (≥4 failures: 67% female). Median time to failure: 5–7 years. Abstract OP0177 @RheumNow #EULAR2025 https://t.co/lchPnTCEx7

• https://x.com/synovialjoints/status/1933124612654604527/photo/1